External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology APAO 2025
Roche and Genentech at

APAO 2025

April 03 - April 06
New Delhi, India
2025.apaophth.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
04:15 AM
Duration 5mins Suryamukhee Hall 401
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Timothy Lai
Ophthalmology | Polypoidal Choroidal Vasculopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:21 AM
Duration 5mins Suryamukhee Hall 401
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment in Diabetic Retinopathy (DR) Without Centre-Involved Diabetic Macular Edema (CI-DME): 2-Year Data From the Phase 3 Pavilion Trial
Timothy Lai
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:27 AM
Duration 5mins Suryamukhee Hall 401
Response of Large or Serous Pigment Epithelial Detachment to Faricimab▼ versus Aflibercept in Patients with Neovascular Age-related Macular Degeneration: A Subgroup Analysis from TENAYA and LUCERNE
Kenneth Fong
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:39 AM
Duration 5mins Suryamukhee Hall 401
Assessment of the Clinical Effects of Anti-Ang-2 With Faricimab▼ Based on Key Outcomes From the YOSEMITE/RHINE Trials and Real-World FARETINA/FARWIDE Studies in Patients With Diabetic Macular Edema (DME)
Paisan Ruamviboonsuk
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:57 AM
Duration 5mins Suryamukhee Hall 401
Long-Term Efficacy and Safety of the Port Delivery Platform with Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Ladder to Portal 5-Year Subgroup Analysis
Shih-Jen Chen
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:45 AM
Duration 5mins Suryamukhee Hall 401
Visual Acuity and Anatomic Improvements at Week 24 Maintained Through Week 72 with Faricimab▼ Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion in the Phase 3 BALATON and COMINO Studies: Results and Patient Case Profiles
Anna Tan
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:57 AM
Duration 5mins Javakusum Hall 303
Study Design and Rationale of the POYANG Study: A Phase III Randomized Clinical Trial of Faricimab▼ for Choroidal Neovascularization Secondary to Pathologic Myopia
Shih-Jen Chen
Ophthalmology | Myopic Choroidal Neovascularization

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 5mins Suryamukhee Hall 401
Faricimab▼ in Diabetic Macular Edema: Results from the RHONE-X Long-Term Extension Trial
Andrew Chang
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:03 AM
Duration 5mins Suryamukhee Hall 401
Port Delivery System With Ranibizumab (PDS) for Continuous Treatment of Diabetic Macular Edema (DME): 2-Year Data From the Phase 3 Pagoda Trial
Andrew Chang
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:09 AM
Duration 5mins Suryamukhee Hall 401
Key Clinical Outcomes with Faricimab▼ in Treatment-naïve Patients with Neovascular Age-Related Macular Degeneration (nAMD): Results from the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies
Chaitra Jayadev
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:12 AM
Duration 5mins Suryamukhee Hall 401
Impact of Early Intraretinal Fluid Reduction on One-Year Outcomes in Diabetic Macular Edema
Gavin Tan
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:18 AM
Duration 5mins Suryamukhee Hall 401
Greater Reduction in Hard Exudates with Faricimab▼ Versus Aflibercept in Patients with Diabetic Macular Edema: Biomarker Results from the Phase 3 YOSEMITE/RHINE Trials
Gavin Tan
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 AM
Duration 5mins Champa Hall 304
Inhibition of Interleukin-6 Receptor (IL-6R) Signaling with Satralizumab▼ in Thyroid Eye Disease (TED): Phase 3 SatraGO-1 and SatraGO-2 Trial Design
Kelvin Chong
Ophthalmology | Thyroid eye disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:48 AM
Duration 6mins Suryamukhee Hall 401
Early Fluid Resolution is Associated with Short- and Long-Term Extended Durability in Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab▼: A post hoc analysis of the TENAYA/LUCERNE Trials
Marten Brelen
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:54 AM
Duration 5mins Suryamukhee Hall 401
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With Diabetic Macular Edema (DME): Year 1 Top-Line Results From the Phase 4 ELEVATUM Study
Shrinivas Joshi
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:17 AM
Duration 6mins Moulshree Hall 402
Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study
Jyotirmay Biswas
Ophthalmology | Uveitic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:24 AM
Duration 6mins Moulshree Hall 402
IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials
Vishali Gupta
Ophthalmology | Uveitic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.